Lantern Pharma (Nasdaq: LTRN) Revenue

Biotechnology Research • Dallas, Texas, United States • 21-50 Employees

Lantern Pharma (Nasdaq: LTRN) revenue & valuation

Annual revenue	$1,475,000
Revenue per employee	$51,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$4,800,000
Total funding	$60,000,000

Key Contact at Lantern Pharma (Nasdaq: LTRN)

Sandra Sinclair

Executive Director Clinical Operations

Company overview

Headquarters	1920 McKinney Ave, Dallas, TX 75201, US
Phone number	+12345678901
Website	lanternpharma.com
NAICS	541714
SIC	873
Keywords	Biotechnology, Biomarkers, Artificial Intelligence, Companion Diagnostics, Precision Medicine, Drug Repurposing, Cancer Drug Development, Patient Stratification, Drug Rescue, Genetic Screen, Precisiononcology
Founded	2013
Employees	21-50
Socials

Lantern Pharma (Nasdaq: LTRN) Email Formats

Lantern Pharma (Nasdaq: LTRN) uses 2 email formats. The most common is {first initial} (e.g., j@lanternpharma.com), used 55% of the time.

Format	Example	Percentage
{first initial}	j@lanternpharma.com	55%
{first name}	john@lanternpharma.com	45%

About Lantern Pharma (Nasdaq: LTRN)

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

C-Suite

Employees by Department

Lantern Pharma (Nasdaq: LTRN) has 16 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore Lantern Pharma (Nasdaq: LTRN)'s funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-02-14	23	$60,000,000

Funding Insights

$60,000,000

Total funding amount

$60,000,000

Most recent funding amount

Number of funding rounds

Lantern Pharma (Nasdaq: LTRN) Tech Stack

Discover the technologies and tools that power Lantern Pharma (Nasdaq: LTRN)'s digital infrastructure, from frameworks to analytics platforms.

Matomo Analytics

Analytics

Embedly

Widgets

Cloudflare

CDN

jQuery

JavaScript libraries

Apple iCloud Mail

Webmail

HTTP/3

Miscellaneous

HSTS

Security

Matomo Tag Manager

Tag managers

Webflow

Page builders

Google Analytics

Analytics

Google Workspace

Adobe Fonts

Font scripts

Frequently asked questions

Lantern Pharma (Nasdaq: LTRN) is located in Dallas, Texas, US.

You can reach Lantern Pharma (Nasdaq: LTRN) at +12345678901.

Lantern Pharma (Nasdaq: LTRN) generates an estimated annual revenue of $1,475,000. This revenue figure reflects the company's market position and business performance in its industry.

Lantern Pharma (Nasdaq: LTRN) has an estimated valuation of $4,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Lantern Pharma (Nasdaq: LTRN) was founded in 2013, making it 13 years old. The company has established itself as a significant player in its industry over this time.

Lantern Pharma (Nasdaq: LTRN) has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Lantern Pharma (Nasdaq: LTRN) has raised a total of $60,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Lantern Pharma (Nasdaq: LTRN)

Sandra Sinclair

Executive Director Clinical Operations

4.8

40,000 users